Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-02-06 DOI:10.1016/j.vaccine.2024.126661

Sonja C. Galetti , Adva Gadoth , Megan Halbrook , Nicole H. Tobin , Kathie G. Ferbas , Anne W. Rimoin , Grace M. Aldrovandi

{"title":"Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures","authors":"Sonja C. Galetti , Adva Gadoth , Megan Halbrook , Nicole H. Tobin , Kathie G. Ferbas , Anne W. Rimoin , Grace M. Aldrovandi","doi":"10.1016/j.vaccine.2024.126661","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, human mpox has made multiple resurges, prompting public health professionals to consider factors that lead to the increased risk for the reemergence of other orthopoxviruses. Due to the genetic similarity between orthopoxviruses, vaccinia vaccines used to prevent smallpox transmission are also indicated and have been used for mpox infection prevention and control. In this study, cross-reactive immunity for mpox was observed among individuals with self-reported history of smallpox vaccination. Differences in mean antigen response among individuals vaccinated in childhood and adulthood versus individuals vaccinated in childhood only were also observed, supporting the hypothesis that childhood smallpox vaccination may not be sufficient in providing long-lasting protection against multiple orthopoxviruses. These results provide insight on the durability of mpox immunogenic proteins and can be used to inform future studies to assess the benefits of reestablishing vaccinia vaccines as standard recommended immunizations, particularly where orthopoxviruses, such as mpox, are endemic.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126661"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24013434","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, human mpox has made multiple resurges, prompting public health professionals to consider factors that lead to the increased risk for the reemergence of other orthopoxviruses. Due to the genetic similarity between orthopoxviruses, vaccinia vaccines used to prevent smallpox transmission are also indicated and have been used for mpox infection prevention and control. In this study, cross-reactive immunity for mpox was observed among individuals with self-reported history of smallpox vaccination. Differences in mean antigen response among individuals vaccinated in childhood and adulthood versus individuals vaccinated in childhood only were also observed, supporting the hypothesis that childhood smallpox vaccination may not be sufficient in providing long-lasting protection against multiple orthopoxviruses. These results provide insight on the durability of mpox immunogenic proteins and can be used to inform future studies to assess the benefits of reestablishing vaccinia vaccines as standard recommended immunizations, particularly where orthopoxviruses, such as mpox, are endemic.

查看原文本刊更多论文

历史天花疫苗接种和m痘交叉反应性免疫：来自儿童期和成年期接触过的卫生保健工作者的证据

近年来，人类痘多次复发，促使公共卫生专业人员考虑导致其他正痘病毒再次出现风险增加的因素。由于正痘病毒之间的遗传相似性，用于预防天花传播的牛痘疫苗也已被用于预防和控制m痘感染。在本研究中，在自我报告有天花疫苗接种史的个体中观察到m痘的交叉反应性免疫。还观察到在儿童期和成年期接种疫苗的个体与仅在儿童期接种疫苗的个体之间的平均抗原应答差异，支持儿童期接种天花疫苗可能不足以提供针对多种正痘病毒的持久保护的假设。这些结果提供了关于m痘免疫原性蛋白持久性的见解，并可用于为未来的研究提供信息，以评估将牛痘疫苗重新建立为标准推荐免疫接种的益处，特别是在正痘病毒（如m痘）流行的地方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.